BioNTech SE (@biontech_group) 's Twitter Profile
BioNTech SE

@biontech_group

Our vision: Harnessing the immune system’s power to turn science into survival.
Data Privacy: bit.ly/4fdYEf6
Imprint: bit.ly/3YmtoUr

ID: 1060984350995550208

linkhttps://biontech.com/ calendar_today09-11-2018 19:55:56

283 Tweet

81,81K Followers

161 Following

Gate.io (@gate_io) 's Twitter Profile Photo
Gate.io
@gate_io

5 hours ago

🔥The 9th Round of Easy Loan, Earn $40 Reward is in progress❗️ ⏰ Promotion Period: January 15th - Feburary 15th, 2025 👉 Register now and check more details at gate.io/campaigns/358

🔥The 9th Round of Easy Loan, Earn $40 Reward is in progress❗️ ⏰ Promotion Period: January 15th - Feburary 15th, 2025 👉 Register now and check more details at gate.io/campaigns/358
BioNTech SE (@biontech_group) 's Twitter Profile Photo
BioNTech SE
@biontech_group

a year ago

We are excited to present updates for programs of our #oncology pipeline at the #ASCO24. This year’s data will be informing the direction of further development of several priority product candidates as well as the design of planned pivotal trials. 👉investors.biontech.de/news-releases/…

We are excited to present updates for programs of our #oncology pipeline at the #ASCO24. This year’s data will be informing the direction of further development of several priority product candidates as well as the design of planned pivotal trials. 👉investors.biontech.de/news-releases/…
BioNTech SE (@biontech_group) 's Twitter Profile Photo
BioNTech SE
@biontech_group

a year ago

The U.S. FDA granted Fast Track designation for our #ADC candidate BNT324/DB-1311 for the treatment of castration-resistant #ProstateCancer. With this, all 3 clinical ADC candidates in our collab with #DualityBio have received Fast Track designation. investors.biontech.de/news-releases/…

The <a href="/US_FDA/">U.S. FDA</a> granted Fast Track designation for our #ADC candidate BNT324/DB-1311 for the treatment of castration-resistant #ProstateCancer. With this, all 3 clinical ADC candidates in our collab with #DualityBio have received Fast Track designation. investors.biontech.de/news-releases/…
BioNTech SE (@biontech_group) 's Twitter Profile Photo
BioNTech SE
@biontech_group

a year ago

We have just announced that our personalized #mRNA candidate BNT111 met its primary endpoint in randomized Ph 2 trial, demonstrating a statistically significant improvement in ORR in patients with anti-PD1 refractory/resistant #melanoma. 👉Read more: investors.biontech.de/news-releases/…

We have just announced that our personalized #mRNA candidate BNT111 met its primary endpoint in randomized Ph 2 trial, demonstrating a statistically significant improvement in ORR in patients with anti-PD1 refractory/resistant #melanoma. 👉Read more: investors.biontech.de/news-releases/…
BioNTech SE (@biontech_group) 's Twitter Profile Photo
BioNTech SE
@biontech_group

9 months ago

We are excited to present updates for our #oncology pipeline at #ESMO24. Presentations feature candidates across multiple modalities which are important backbones for our combination treatment strategy & may open up new synergistic mechanisms of action.👉investors.biontech.de/news-releases/…

We are excited to present updates for our #oncology pipeline at #ESMO24. Presentations feature candidates across multiple modalities which are important backbones for our combination treatment strategy &amp; may open up new synergistic mechanisms of action.👉investors.biontech.de/news-releases/…
BioNTech SE (@biontech_group) 's Twitter Profile Photo
BioNTech SE
@biontech_group

7 months ago

Advancing our oncology strategy: by strengthening next-gen immuno-modulator capabilities, we’re enhancing one core pillar of our oncology strategy.With investigational assets like BNT327/PM8002,our pipeline aims to build a new backbone in immuno-oncology.investors.biontech.de/de/news-releas…

BioNTech SE (@biontech_group) 's Twitter Profile Photo
BioNTech SE
@biontech_group

3 months ago

We aim to tackle one of the most lethal cancers worldwide: #LungCancer. This week, we are joining the global community at the #ELCC25 presenting new data for our PD-L1/VEGF-A bispecific antibody candidate in metastatic #SCLC. 👉Learn more about the data: investors.biontech.de/encrypted-node…

We aim to tackle one of the most lethal cancers worldwide: #LungCancer. This week, we are joining the global community at the #ELCC25 presenting new data for our PD-L1/VEGF-A bispecific antibody candidate in metastatic #SCLC. 👉Learn more about the data: investors.biontech.de/encrypted-node…
BioNTech SE (@biontech_group) 's Twitter Profile Photo
BioNTech SE
@biontech_group

20 days ago

We are partnering with Bristol Myers Squibb to jointly develop and commercialize our PD-L1xVEGF bispecific #antibody candidate BNT327. Combining our expertise, resources, and global reach, we aim to bring novel combination therapies to patients with #cancer. 🚀 investors.biontech.de/news-releases/…

We are partnering with <a href="/bmsnews/">Bristol Myers Squibb</a> to jointly develop and commercialize our PD-L1xVEGF bispecific #antibody candidate BNT327. Combining our expertise, resources, and global reach, we aim to bring novel combination therapies to patients with #cancer. 🚀 investors.biontech.de/news-releases/…